About Garry Nicholson
Garry Nicholson is a director at TScan Therapeutics.
Form D filings name Garry Nicholson as a director at Avenzo Therapeutics.
Garry Nicholson reports to the SEC as a director of 7 public companies, including Day One Biopharmaceuticals (DAWN), G1 Therapeutics (GTHX) and NextCure (NXTC).
Garry Nicholson first appears on SEC filings in 2015.
Experience
This experience comes from SEC filings. The years are when the filings name Garry Nicholson in the role, so the role may have started earlier or lasted longer.
TI
TScan Therapeutics, Inc.
Director
2024 – 2026 · Public company (TCRX)
DI
Day One Biopharmaceuticals, Inc.
Director
2022 – 2026 · Public company (DAWN)
GI
G1 Therapeutics, Inc.
Director
2018 – 2024 · Public company (GTHX)
NI
NextCure, Inc.
Director
2020 – 2023 · Public company (NXTC)
TI
Turning Point Therapeutics, Inc.
Director
2020 – 2022 · Public company (TPTX)
FI
Five Prime Therapeutics, Inc.
Director
2017 – 2021 · Public company (FPRX)
TI
Tesaro, Inc.
Director
2015 – 2019 · Public company (TSRO)
Key Colleagues at Startups
The people Garry Nicholson works with at each company, as listed on that company's latest Form D.
Avenzo Therapeutics, Inc. · Form D, Sep 5, 2025
CG
Carl Gordon
Director
PM
Patrick Machado
Director
JL
Judith Li
Director
PT
Paolo Tombesi
Executive officer
MH
Mohammad Hirmand
Executive officer
SG
Simeon George
Director
SL
Scott Lipman
Executive officer
AC
Athena Countouriotis
Executive officer and director
BS
Brian Sun
Executive officer
JA
Jakob Dupont, M.D., M.A.
Director